https://www.selleckchem.com/pr....oducts/trilaciclib.h
Although graft and patient outcomes with belatacept have been relatively well documented, the decision to use belatacept for kidney transplant recipients rests in part on the patient experience with a monthly infusion. These details are poorly documented in the literature. This study describes the personal impact of using belatacept to facilitate shared and informed decision-making regarding the choice of immunosuppression among transplant providers, transplant coordinators, and patients. This study finds that participants are gener
Curtir
Comentario
Compartilhar
